News

Viking Therapeutics and Roche are developing drugs for obesity and diabetes to challenge Eli Lilly and Novo Nordisk’s market duopoly.

RHHBY's enicepatide cut HbA1c and body weight in a phase II study, strengthening its obesity ambitions as it advances the drug into phase III.

Viking Therapeutics surged more than 26% on fresh GLP-1 maintenance data while every major obesity peer from Eli Lilly to Novo Nordisk barely registered a pulse, raising a pointed question about whether this catalyst belongs to Viking alone or signals something bigger.

When investing in a dividend stock, it's important to consider not just the yield, but also the potential for dividend growth and overall risk.

The company sees the latest trial results reinforcing its ambitions to rapidly develop a portfolio of medicines for people with obesity, diabetes and cardiovascular disease.

NVO's CagriSema delivers greater weight loss than Eli Lilly's tirzepatide in T2D and 21% weight loss in obesity, strengthening its late-stage pipeline.

A $6.5B Eli Lilly biomanufacturing facility broke ground at Houston’s Generation Park, Texas’ largest pharmaceutical investment to date.

Alkermes’ results heightened anticipation for a coming readout in 2027. Elsewhere, AbbVie leaned into AI drug discovery and the FDA expanded use of Eli Lilly’s breast cancer pill.

Ken Langone, chairman and president of Invemed Associates and a co-founder of Home Depot (NYSE:HD), used a CNBC Squawk Box appearance on September 22, 2026 to say that his Eli Lilly (NYSE:LLY) position is now pushing his Home Depot stake for top billing in his portfolio. Langone said, “I think Lilly’s going to be a […]

Merck (MRK) stock gained about 89% in the year from mid-September 2025, against a 17.1% price gain for the S&P 500. It also beat Johnson & Johnson (JNJ), up 58%, and Eli Lilly (LLY), up 54%. The signs were public long before the run, in what management kept saying about its drug pipeline. The reported sales told a different story.

Viking Therapeutics and Roche are developing drugs for obesity and diabetes to challenge Eli Lilly and Novo Nordisk’s market duopoly.

Roche (USOTC:RHHBY) has reported positive results from a mid-stage clinical trial of its experimental obesity treatment enicepatide, with patients who have type 2 diabetes achieving average weight loss of 15. 5% alongside improvements in blood sugar control.

Johnson & Johnson (JNJ) stock has returned 58% over the past twelve months, second best in a group of six health care companies. Its revenue growth ranks only fourth of the six. Three peers grew faster and returned less, Eli Lilly among them. The price is a bet that the rest of the business keeps growing once shrinking STELARA sales stop dragging on the total.

The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was up 0.1%, and the actively tra

CEO Dave Ricks told CNBC that 700,000 seniors have started weight loss treatments since Medicare coverage launched in July

Eli Lilly Stock Gets Powerful Boost From Foundayo as Oral Weight-Loss Pill Gains Ground

About 700,000 seniors have started GLP-1 treatments since Medicare coverage began in July.

Viking Therapeutics and Roche both reported positive obesity drug data early Tuesday. Viking stock surged. Eli Lilly and Novo fell.

Viking Therapeutics’ experimental obesity drug showed it could preserve most patients’ prior weight loss with less frequent dosing.

Novo is shaping a future beyond its Wegovy franchise as CEO Maziar Mike Doustdar looks to turn the drugmaker’s fortunes around.

Eli Lilly just posted a quarter that crushed estimates on every major metric, yet the stock has spent the past month getting punished anyway. One of Wall Street's biggest banks thinks the selloff created the most compelling entry point in the GLP-1 giant's recent history.

The facility, part of Lilly's $50 billion domestic manufacturing push, will produce active ingredients for Foundayo and other medicines

Twist Bioscience Corporation (NASDAQ:TWST) is on the cusp of gaining significant exposure to the rapidly evolving artificial intelligence (AI)-driven drug discovery ecosystem. On September 16, the company confirmed a strategic partnership with Lilly TuneLab, a platform created by Eli Lilly and Company (NYSE:LLY). As part of the strategic partnership, Twist will provide antibody characterization data […]

While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient spending, slowing demand, or weak competitive positioning.

Key Stats for Eli Lilly StockPrice change for Eli Lilly stock in last 6 months: 27%$LLY Stock Price as of Sep. 21: $1,16552-Week High: $1,292$LLY Stock Price Target: $1,325What Happened?Eli Lilly (LLY) stock is drawing fresh attention today after Guggenheim raised its price target to $1,284 from $1,273 and maintained a Buy rating.

Eli Lilly (LLY) closed at $1 in the latest trading session, marking a +1.04% move from the prior day.

A surge in U.S.-China transactions is drawing scrutiny in Washington, where some lawmakers are pushing to slow the pace of investment.

The pharmaceutical giant's new Houston-based facility will create 600 jobs, boosting life sciences in Generation Park.

Chair and CEO Dave Ricks told CNBC that about one-third of new patients starting a GLP-1 tablet are now on Foundayo, and that Lilly’s share of that oral market is still rising week by week.

Oura Inc. is pitching its U.S. initial public offering to investors, aiming for a fully diluted value of about $15.62 billion as it sizes up demand for consumer tech deals. The smart-ring maker plans to price next week, as markets...